Akebia Therapeutics Files 8-K
Ticker: AKBA · Form: 8-K · Filed: May 8, 2025 · CIK: 1517022
| Field | Detail |
|---|---|
| Company | Akebia Therapeutics, Inc. (AKBA) |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, financial-reporting
Related Tickers: AKBA
TL;DR
AKBA filed an 8-K on May 8th for financial updates.
AI Summary
Akebia Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies Akebia Therapeutics' official reporting of its operational and financial status to the SEC, providing transparency to investors.
Risk Assessment
Risk Level: low — The filing is a standard SEC disclosure and does not inherently present new risks.
Key Players & Entities
- Akebia Therapeutics, Inc. (company) — Registrant
- May 8, 2025 (date) — Date of earliest event reported
- 245 First Street Cambridge, Massachusetts 02142 (address) — Principal executive offices
- 001-36352 (company_id) — SEC File Number
FAQ
What specific financial results are being reported by Akebia Therapeutics in this 8-K?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific financial figures within this excerpt.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is May 8, 2025.
What is Akebia Therapeutics' principal executive office address?
Akebia Therapeutics' principal executive office is located at 245 First Street Cambridge, Massachusetts 02142.
What is the SEC file number for Akebia Therapeutics?
The SEC file number for Akebia Therapeutics is 001-36352.
What is the standard industrial classification for Akebia Therapeutics?
The standard industrial classification for Akebia Therapeutics is PHARMACEUTICAL PREPARATIONS [2834].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Akebia Therapeutics, Inc. (AKBA).